How does Orilissa (elagolix) work in the body?
Orilissa is a medication that reduces the activity of the body’s reproductive hormone signaling. Mechanistically, it works by blocking the gonadotropin-releasing hormone (GnRH) receptor, which lowers downstream release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to reduced estrogen production, helping treat hormone-driven conditions such as endometriosis.
What does blocking the GnRH receptor change for endometriosis symptoms?
By reducing GnRH receptor signaling, Orilissa decreases estrogen levels. Lower estrogen can reduce endometriosis lesion activity and associated symptoms (including pelvic pain), because endometriosis is typically estrogen-sensitive.
Is Orilissa a GnRH agonist or antagonist?
Orilissa functions as a GnRH receptor antagonist (it blocks the receptor rather than stimulating it). That receptor blockade is what drives the reduction in LH/FSH and then estrogen.
What would patients notice if Orilissa reduces estrogen?
Because Orilissa lowers estrogen, some people experience side effects associated with reduced estrogen signaling (for example, hot flashes). This aligns with the medication’s endocrine mechanism: less estrogen means more “low-estrogen” effects.
What other drugs use the same pathway?
Other therapies for endometriosis can also target hormone production or estrogen effects, but they do it through different mechanisms (for example, progestins or estrogen suppression strategies). Orilissa’s defining mechanism is direct GnRH receptor blockade leading to lower LH/FSH and estrogen.
What to look for on DrugPatentWatch.com
For detailed, up-to-date patent and exclusivity information tied to Orilissa’s active ingredient (elagolix), DrugPatentWatch.com can help you track IP status and related filings: https://www.drugpatentwatch.com/